Our hyaluronic acid matrix ingredient Dermial® demonstrates unique skin “glow” effect in a randomized clinical trial

Bioiberica today reveals insights from its debut clinical trial on Dermial® – the first hyaluronic acid (HA) matrix ingredient for skin and beauty innovation. Among the outcomes being showcased are Dermial®’s unique ‘glow’ effect, skin hydration benefit and action against wrinkles, all achieved at only 60 mg/day.[1] The company is presenting these findings at the Annual Meeting of the Society for Investigative Dermatology (SID) in Dallas, US, this week and the team will also be discussing the findings with visitors at Vitafoods Europe in Geneva. At both events, Bioiberica will highlight how this latest clinical evidence underscores the innovation potential of Dermial® in the global nutricosmetics arena.

‘Glowing’ results

Dermial® is comprised of a high concentration of HA (60-75%) plus other beneficial constituents, including sulfated glycosaminoglycans and collagen, that work in synergy to deliver all the benefits of HA, and more. Previous in vitro research has shown that Dermial® brings powerful nourishing and moisturising properties to help maintain the health and nutrition of the skin.^{[2], [3], [4], [5]}      

This new clinical trial explored the effects of a daily oral supplement containing 60 mg Dermial® on signs of skin ageing in healthy women. In total, 60 women aged between 35 and 65 years participated in the study and were split into two groups: one receiving 60 mg of Dermial® daily for 12 weeks, and the other a placebo. The trial revealed that the daily supplement had a unique ‘glow’ effect on the skin – increasing skin brightness by 20% at six weeks and almost 34% at twelve weeks.  Additionally, statistically significant differences in wrinkle reduction were observed between Dermial® and the placebo group after only 6 weeks.  Hydration of the stratum corneum (the outermost layer of the epidermis), scaliness (dryness), Tª (skin temperature) and erythema index (redness of skin) were also significantly improved in the Dermial® group versus baseline at six weeks.    

High consumer satisfaction

Daniel Martínez-Puig, Head of R&D Human and Animal Health at Bioiberica and one of the investigators in the trial says: “Taken together, these results confirm that a low daily dose of Dermial® is safe and supports the homeostasis, appearance and integrity of ageing skin. But that’s not all. We also assessed satisfaction scores in both groups. Consumer satisfaction was significantly higher in supplemented women (69%) compared to placebo (42%), indicating that they experienced tangible benefits when using Dermial®.”

An expanding era where beauty meets nutrition

“This is an exciting time for innovation in the nutricosmetics space,” says Antonio Vendrell, Marketing Director at Bioiberica. “There is ever-growing demand for beauty-from-within solutions, from consumers of all demographics and backgrounds – and the market craves science-backed and convenient solutions. We’re therefore extremely excited to share this latest compelling evidence from our clinical trial and soaring consumer satisfaction scores, as it gives our partners confidence that, once they’ve experienced Dermial®, consumers will be back for more.”

Visitors to Vitafoods Europe are invited to stop by Bioiberica’s booth (F142) to dive deeper into the science behind this revolutionary ingredient. For more information about Bioiberica’s healthcare portfolio, please visit: Bioiberica’s Branded Ingredients.

These statements have not been evaluated by competent food authorities. The product is not intended to diagnose, treat, cure, or prevent any disease.  This information is only for business-to-business use and not meant to be addressed to final consumers.